Zura Bio Limited ZURA
3.99 USD +0.05 (+1.27%)
At closeNov 3, 2026, 4:01 PM EST
3.99 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
3.90 Day range 4.13
3.25 52-week range 7.44
- YTD
- -23.85%
- 1 year
- +8.42%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 14.29 +258.0% upside
Now 3.99
- Target (low)
- 5.00
- Target (mean)
- 14.29
- Target (high)
- 26.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy1
- Buy6
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 9
- 2 months ago 7
- 3 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Nov 18, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Nov 11, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Nov 8, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 4, 2024 | Leerink Partners | Initiated | — | Outperform |
| Oct 21, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Oct 18, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Sep 19, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Sep 5, 2024 | HC Wainwright & Co. | Initiated | — | Neutral |
| Aug 15, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jun 17, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jun 12, 2024 | Cantor Fitzgerald | Initiated | — | Overweight |
| May 10, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| May 3, 2024 | Piper Sandler | Initiated | — | Overweight |
| Apr 1, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Oct 10, 2023 | Ladenburg Thalmann | Initiated | — | Buy |
| Aug 25, 2023 | Oppenheimer | Initiated | — | Outperform |
| Aug 15, 2023 | Raymond James | Maintained | Strong Buy | Strong Buy |
| Jun 22, 2023 | Guggenheim | Initiated | — | Buy |
| Jun 14, 2023 | Chardan Capital | Initiated | — | Buy |
| May 24, 2023 | Raymond James | Initiated | — | Strong Buy |